CD19 and B-cell non-Hodgkin lymphoma: Here, we demonstrate that CD19-targeted HSP90 inhibitor 17-DMAG nanoparticle combined with TKI not only targets cancer cells effectively but also triggers an antitumor T-cell immune response in murine models of BCR-ABL1+ B-ALL and B-cell lymphoma.